Modality
Radioligand
MOA
CD3xCD20
Target
AuroraA
Pathway
Cell Cycle
CTCLACCFL
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Mar 2028
Phase 1Current
NCT03494246
1,688 pts·ACC
2022-07→2025-11·Completed
NCT03493288
2,887 pts·FL
2017-10→2028-03·Active
4,575 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-037mo agoFast Track· CTCL
2025-11-194mo agoPh2 Data· ACC
2028-03-252.0y awayPh2 Data· FL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Active
P1/2
Complet…
Catalysts
Fast Track
2025-09-03 · 7mo ago
CTCL
Ph2 Data
2025-11-19 · 4mo ago
ACC
Ph2 Data
2028-03-25 · 2.0y away
FL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03494246 | Phase 1/2 | ACC | Completed | 1688 | ACR20 |
| NCT03493288 | Phase 1/2 | FL | Active | 2887 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |